Entera Bio announces presentation of PK data for GLP-2 tablet treatment

Entera Bio (ENTX) announced the presentation of a poster titled “A First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” at the 47th European Society for Clinical Nutrition & Metabolism, ESPEN, Congress in Prague, Czech Republic, highlighting pharmacokinetic data relating to its oral GLP-2 analog program. Key Data Presented at ESPEN: Extended Half-Life: OPK-8801003 GLP-2 tablet demonstrated a plasma half-life of approximately 15 hours in minipigs, representing an approximate 18-fold improvement over teduglutide, which has a half-life of only 0.85 hours in the same species. Robust Oral Bioavailability: Following oral administration of OPK-8801003 tablets in minipigs, peak plasma concentrations reached ~200 ng/ml, substantially exceeding the reported Cmax of 36.8 ng/ml for daily 0.05 mg/kg teduglutide subcutaneous injection in humans. Sustained Exposure: Systemic exposure was maintained for more than 24 hours with relatively low variability, supporting once-daily oral dosing. Favorable Safety Profile: No signs of toxicity were observed in the preclinical studies.